A MULTICENTER TRIAL OF INTERLEUKIN-2 AND LOW-DOSE CYCLOPHOSPHAMIDE IN HIGHLY CHEMOTHERAPY-RESISTANT MALIGNANCIES

被引：20
|
作者：
LINDEMANN, A
HOEFFKEN, K
SCHMIDT, RE
DIEHL, V
KLOKE, O
GAMM, H
HAYUNGS, J
OSTER, W
BOEHM, M
FRANKS, CR
HERRMANN, F
MERTELSMANN, R
机构：
[1] UNIV COLOGNE,DEPT MED I,D-5000 COLOGNE 41,FED REP GER
[2] UNIV HANOVER,DEPT IMMUNOL & TRANSFUS MED,D-3000 HANOVER,FED REP GER
[3] UNIV ESSEN GESAMTHSCH,DEPT INTERNAL MED CANC RES,D-4300 ESSEN 1,FED REP GER
[4] CETUS CORP,EUROCETUS,AMSTERDAM,NETHERLANDS
来源：
CANCER TREATMENT REVIEWS | 1989年 / 16卷
关键词：
D O I：
10.1016/0305-7372(89)90023-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：53 / 57
页数：5
相关论文
共 50 条
  • [1] LOW-DOSE CYCLOPHOSPHAMIDE AND LOW-DOSE INTERLEUKIN-2 FOR MALIGNANT-MELANOMA
    MITCHELL, MS
    KEMPF, RA
    HAREL, W
    SHAU, H
    BOSWELL, WD
    LIND, S
    DEAN, G
    MOORE, J
    BRADLEY, EC
    BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 1989, 65 (01) : 128 - 144
  • [2] Effects of low-dose recombinant interleukin-2 in human malignancies
    Lissoni, P
    CANCER JOURNAL FROM SCIENTIFIC AMERICAN, 1997, 3 : S115 - S120
  • [3] LOW-DOSE RECOMBINANT INTERLEUKIN-2 AND LOW-DOSE CYCLOPHOSPHAMIDE IN METASTATIC BREAST-CANCER
    SPICER, DV
    KELLEY, A
    HERMAN, R
    DEAN, G
    STEVENSON, L
    MITCHELL, MS
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1992, 34 (06) : 424 - 426
  • [4] EFFECTIVENESS AND TOLERABILITY OF LOW-DOSE CYCLOPHOSPHAMIDE AND LOW-DOSE INTRAVENOUS INTERLEUKIN-2 DISSEMINATED MELANOMA
    MITCHELL, MS
    KEMPF, RA
    HAREL, W
    SHAU, H
    BOSWELL, WD
    LIND, S
    BRADLEY, EC
    JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (03) : 409 - 424
  • [5] SUCCESSFUL THERAPY OF MELANOMA WITH A REGIMEN OF LOW-DOSE CYCLOPHOSPHAMIDE AND INTERLEUKIN-2
    MITCHELL, MS
    KEMPF, RA
    HAREL, W
    SHAU, H
    BOSWELL, WD
    LIND, S
    DEAN, G
    MOORE, J
    BRADLEY, EC
    MOLECULAR AND CELLULAR NETWORKS FOR CANCER THERAPY, 1989, 857 : 61 - 74
  • [6] High-dose interleukin-2 may not be superior to low-dose interleukin-2 plus interferon
    Alikhan, M
    Spencer, HJ
    Kohli, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 6267 - 6268
  • [7] IMMUNOLOGICAL EFFECTS OF THERAPY WITH LOW-DOSE CYCLOPHOSPHAMIDE (CY) AND RECOMBINANT INTERLEUKIN-2 (IL2)
    HAREL, W
    SHAU, H
    HADLEY, C
    STAHLBERG, J
    REISFELD, R
    CHERESH, D
    MITCHELL, M
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 401 - 401
  • [8] Low-Dose Interleukin-2 for Refractory Autoimmune Hepatitis
    Lim, Tiong Y.
    Martinez-Llordella, Marc
    Kodela, Elisavet
    Gray, Elisabeth
    Heneghan, Michael A.
    Sanchez-Fueyo, Alberto
    HEPATOLOGY, 2018, 68 (04) : 1649 - 1652
  • [9] Diabetes mellitus induced by low-dose interleukin-2
    Soni, N
    Meropol, NJ
    Porter, M
    Caligiuri, MA
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1996, 43 (01) : 59 - 62
  • [10] Low-dose interleukin-2 for systemic lupus erythematosus?
    Wallace, Daniel J.
    LANCET RHEUMATOLOGY, 2019, 1 (01): : E7 - E8
12345